Hudson Bay Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Hudson Bay Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$216K	Buy	+20,208	New	+$195K	﹤0.01%	1086
2025 Q2	–	Sell	-182,734	Closed	-$1.13M	–	1457
2025 Q1	$1.13M	Buy	+182,734	New	+$1.42M	﹤0.01%	899
2024 Q3	–	Sell	-48,720	Closed	-$200K	–	919
2024 Q2	$200K	Buy	+48,720	New	+$412K	﹤0.01%	663

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hudson Bay Capital Management's ELTX Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Elicio Therapeutics (ELTX) in Q1 2026: 20,208 shares worth $216K. The stake represents ﹤0.01% of the portfolio and ranks #1086 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in ELTX as recently as Q1 2025.

Hudson Bay Capital Management first reported a position in ELTX in Q2 2024 and has held it in 3 quarters since. The position peaked at $1.13M in Q1 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Hudson Bay Capital Management held 20,208 shares of Elicio Therapeutics worth $216K as of Q1 2026.
Elicio Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
Elicio Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1086 holding.
Hudson Bay Capital Management first reported a position in Elicio Therapeutics in Q2 2024 and has held it in 3 quarters since.
Hudson Bay Capital Management's Elicio Therapeutics position peaked at $1.13M in Q1 2025.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.